Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Double-Dummy Phase II Study of Single Dose HDIT101 versus Standard of Care Valaciclovir in Patients with Chronic Recurrent Anogenital HSV-2 Infection

Next Previous
Trial Profile

A Randomized, Double-Blind, Double-Dummy Phase II Study of Single Dose HDIT101 versus Standard of Care Valaciclovir in Patients with Chronic Recurrent Anogenital HSV-2 Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HDIT-101 (Primary) ; Valaciclovir
  • Indications Herpes genitalis; Herpes simplex virus type 2 infections
  • Focus Therapeutic Use
  • Acronyms MATCH-2
  • Sponsors Heidelberg ImmunoTherapeutics

Most Recent Events

  • 21 Nov 2021 Status changed from active, no longer recruiting to completed.
  • 05 Nov 2020 Status changed from recruiting to active, no longer recruiting.
  • 19 Nov 2019 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top